Development of dual PLD1/2 and PLD2 selective inhibitors from a common 1,3,8-Triazaspiro[4.5]decane Core: discovery of Ml298 and Ml299 that decrease invasive migration in U87-MG glioblastoma cells

J Med Chem. 2013 Mar 28;56(6):2695-9. doi: 10.1021/jm301782e. Epub 2013 Mar 13.

Abstract

An iterative parallel synthesis effort identified a PLD2 selective inhibitor, ML298 (PLD1 IC50 > 20000 nM, PLD2 IC50 = 355 nM) and a dual PLD1/2 inhibitor, ML299 (PLD1 IC50 = 6 nM, PLD2 IC50 = 20 nM). SAR studies revealed that a small structural change (incorporation of a methyl group) increased PLD1 activity within this classically PLD2-preferring core and that the effect was enantiospecific. Both probes decreased invasive migration in U87-MG glioblastoma cells.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Benzamides / chemistry*
  • Benzamides / metabolism
  • Benzamides / pharmacokinetics
  • Benzamides / pharmacology*
  • Cell Line, Tumor
  • Cell Movement / drug effects*
  • Drug Discovery*
  • Enzyme Inhibitors / chemistry
  • Enzyme Inhibitors / metabolism
  • Enzyme Inhibitors / pharmacokinetics
  • Enzyme Inhibitors / pharmacology
  • Glioblastoma / pathology*
  • Humans
  • Neoplasm Invasiveness
  • Phospholipase D / antagonists & inhibitors*
  • Spiro Compounds / chemistry*
  • Spiro Compounds / metabolism
  • Spiro Compounds / pharmacokinetics
  • Spiro Compounds / pharmacology*

Substances

  • 3,4-difluoro-N-(2-(1-(3-fluorophenyl)-4-oxo-1,3,8-triazaspiro(4.5)decan-8-yl)ethyl)benzamide
  • Benzamides
  • Enzyme Inhibitors
  • ML299
  • Spiro Compounds
  • phospholipase D2
  • Phospholipase D
  • phospholipase D1